Zantac 75 Efferdose
This article was originally published in The Tan Sheet
Executive Summary
Effervescent ranitidine 75 mg tablet was not withdrawn from sale by Warner-Lambert due to safety or efficacy reasons, FDA says in a June 21 Federal Register notice, clearing the way for ANDA approvals. Although the OTC was approved in February 1998 for heartburn treatment and received a prevention indication in March 1999, W-L has never marketed it. Responding to a citizen petition filed in February by regulatory strategist Thomas Blake, PhD, FDA determines "never marketing an approved drug product is equivalent to withdrawing the drug product from sale" (1"The Tan Sheet" March 13, In Brief). The agency will keep the product in the Orange Book's "Discontinued Drug Product List"
You may also be interested in...
Zantac 75 Efferdose petition
Regulatory strategist Thomas Blake, PhD, asks FDA whether Warner-Lambert is not marketing Zantac 75 Efferdose due to "reasons of safety or efficacy" in a Feb. 29 citizen petition. The effervescent ranitidine 75 mg product initially was approved for heartburn treatment in February 1998 and was granted a prevention indication in March 1999. Warner-Lambert says the status of the product is unclear
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands